[Previous Months][Date Index][Thread Index][Join - Register][Login]
[Message Prev][Message Next][Thread Prev][Thread Next]

[IP] Advances in inhalation therapy?



I can't vouch for the authenticity of this but thought it would be of 
interest. If it is authentic, we should be hearing MUCH MORE about it very 
soon. I found it this morning on the Yahoo PFIZER message board. Let's hope 
and pray that it isn't simply a stock 'pump and dump' scheme.
Regards,
 Gilbert Linkswiler 45 years T1, pumping since May 24, 2000

Abstract Type: Oral Abstract Presentation: Clinical Diabetes, Type 1 
Abstract Category: Clinical Diabetes: Therapeutics/New Technology 

Abstract Schedule: 10:15 AM-12:15 PM, 6/10/2000 

AIR Insulin: Complete Diabetes Therapy Via Inhalation of Fast-Acting and 
Slow-Acting Dry Powder Aerosols 
JEFF HRKACH, RICK BATYCKY, DONGHAO CHEN, DAN DEAVER, KATHARINA ELBERT, LLOYD 
JOHNSTON, ROSEMARY A.
KOVALESKY, JACKIE NICE, JEN SCHMITKE, KEVIN STAPLETON, DAVID EDWARDS 

The systemic administration of insulin via inhalation is an attractive 
alternative to injection. Several groups have been developing fast-acting, 
meal-time insulin via
dry powder or liquid aerosols. Using unique porous dry powder aerosol 
technology, AIR has developed both fast-acting and slow-acting pulmonary 
insulin
formulations.
The AIR technology produces particles with a low density (< 0.1 g/cc), large 
geometric particle size (10-20 um) and small aerodynamic size (1-3 um).
Therefore, AIR particles can be very easily aerosolized from a simple, 
inexpensive inhalation device and efficiently delivered to the deep lung (AIR 
powder
deposition in humans is greater than 50% of the nominal dose) providing 
excellent systemic absorption and high bioavailability of insulin.
The AIR inhaler possesses the size and approximate shape of a magic marker 
pen and is easily carried in a convenient plastic case containing the 
blister-packed
insulin. The inhaler requires no power source other than a patient's breath 
and is very simple to use. Because large amounts of powder can be easily 
delivered in
a single breath, one or two puffs can administer the required dose for 
meal-time or basal-level insulin control.
The insulin powders are room-temperature stable (monomer content >99% and A21 
desamido product < 2%) in foil-foil blister packs and exhibit excellent
animal bioavailability (see Table). The sustained release (slow-acting) AIR 
insulin exhibits a PK profile (in rats) similar to Humulin‚ L, whereas the PK 
profile
of the fast-release AIR insulin is similar to Humulin R.1Multiple of systemic 
insulin concentration above baseline at 8 h post-dose.
2100 ug insulin nominal dose, via insufflation. 

------------------------------------------------------------------------------
--
----------------------------------------------------------
for HELP or to subscribe/unsubscribe, contact: HELP@insulin-pumpers.org
send a DONATION http://www.Insulin-Pumpers.org/donate.shtml